EXPERIENCE WITH DEFERASIROX FOR IRON OVERLOAD AFTER RED BLOOD CELL TRANSFUSION

DOI 18 References

Bibliographic Information

Other Title
  • 輸血後鉄過剰症に対する経口鉄キレート剤（deferasirox）の使用経験

Search this article

Description

We analyzed the effect of deferasirox (DFX) therapy in 73 patients with a nonelective need for blood transfusion. Median age was 67 years (20-89). Median observation period was 182 days (19-428). Among 73 evaluable patients, 3 were able to discontinue DFX after achieving a predetermined treatment goal (SF<500), 19 had significant decrease in SF, and 17 failed to show significant response. Among 36 patients who were able to continue DFX for more than 6 months, serum ferritin (SF) levels were decreased by an average of 103ng/ml per month. In contrast, 17 patients (23.3%) discontinued DFX because of adverse effects, including digestive organ symptoms and renal function abnormalities. There were difficulties in sufficiently increasing the dose of DFX because of adverse effects. In order to fully perform chelation therapy with DFX, it is important to start administration of DFX from a low dose at an early stage of iron overload.<br>

Journal

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top